Blogs

Fetal fraction (FF)—the percentage of cell-free fetal DNA in maternal plasma—is a critical factor affecting the sensitivity and reliability of non-invasive prenatal testing (NIPT). Read More

In the rapid evolution of prenatal genomics, non-invasive prenatal testing (NIPT) has emerged as one of the most groundbreaking advancements. It enables fetal chromosomal screening through maternal blood sampling and analysis of cell-free DNA (cfDNA). Read More

Homologous Recombination Deficiency (HRD) refers to a condition where a cell's ability to repair DNA double-strand breaks via the homologous recombination repair (HRR) pathway is compromised. This deficiency can lead to genomic instability, a hallmark of many cancer types. Read More

In the field of cancer genomics research, ensuring accurate and reproducible results is critical for the development and validation of high-performance assays. As genomic technologies such as Next-Generation Sequencing (NGS) continue to evolve, the demand for reliable and standardized reference materials has grown. Read More

You may hear your doctor say HRD positive or HRD negative when talking about cancer. HRD positive means your cells cannot fix DNA damage well. HRD negative means your cells fix DNA damage easily. About half of patients are in each group:Knowing your HRD status helps doctors choose your treatment. Read More

You can use HRD testing to see if a tumor cannot fix DNA. This test helps doctors pick the best treatment for you. It is very useful for ovarian, breast, and prostate cancer. Many patients with non-BRCA1/2 gene changes show HRD positivity. Germline mutations often cause even higher rates. Read More